Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets
ATLANTA, Feb. 10 /PRNewswire/ -- Food retailers concerned about pathogens such as Salmonella, Listeria, and E. coli
in their perishable departments can now outsource "deep cleaning" services to Chemstar Corporation, a company that operates food safety and sanitation programs throughout the Uni...
Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
Importance of cleaning floor drains often underestimated in food safety and sanitation protocols
ATLANTA, Sept. 24 /PRNewswire/ -- Recent media coverage of food recalls
and outbreaks has consumers concerned about food safety. As a result of the
increased scrutiny, many f...
K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers' Grains
MANHATTAN, Kan., Aug. 21 /PRNewswire-USNewswire/ -- A research team
headed by Kansas State University E. coli
O157:H7 expert T.G. Nagaraja has
been tapped by the U.S. Department of Agriculture to study both the
connection between feeding distillers' grains and E. coli
0157:H7 in cattle
DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
Company's BAX(R) System Part of R&D Agreement
WILMINGTON, Del., Feb. 21 /PRNewswire-FirstCall/ -- DuPont (NYSE: DD )
and the United States Department of Agriculture (USDA) Agricultural
Research Service (ARS) are teaming up to find new ways to detect an E. coli
strain in beef that...
July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
...poisoning. The July issue of Mayo Clinic Women's HealthSource provides an overview of food storage safety and how to avoid bad bacteria, such as E. coli
Safe food storage matters. While diarrhea and vomiting caused by food poisoning usually resolve without treatment, about 325...
Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
...ccessful delivery of the active hairpin RNA component by the bacterial system. Cequent developed the current tk RNAi candidate on the basis of an E. coli
delivery platform obtained from the laboratory of Patrice Courvalin at the Institut Pasteur. Cequent is planning to start a Phase I clinical trial fo...
GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.
...m other technologies. The GES
is designed for a host of individual diseases, the current priorities being
Mad Cow disease, Chronic Wasting Disease, E. coli
0157:H7 and Johne's disease,
all diseases affecting cattle worldwide. For more information, contact Dr.
Tony Milici at 303-463-6371 or Al Goldsmith of...
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
...cteria, including MRSA, penicillin-resistant
Streptococcus pneumoniae (PRSP), vancomycin-resistant Enterococcus (VRE),
multidrug resistant Escherichia coli
and other difficult-to-treat
pathogens. Introduced more than 50 years ago, tetracyclines remain among
the most commonly used antiinfective agents to c...
Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
...nter the clinic in
Wacker's proprietary E. coli
secretion system is a well-established
technology ... At the core of
the technology is a proprietary E. coli
K12-strain, developed by Wacker, to
secrete recomb...ts obtained to
date underscore the power of our E. coli
secretion technology and highlight
Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
...entration (MIC) of clarithromycin for ESBL-producing strains
of Escherichia coli
by a factor of 250-750. NAB 739, the lead compound of
the second series, ac... efficacy of both lead compounds has been verified using an
experimental E. coli
peritonitis model in mice, and we are now talking to
potential partners to ...
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
...ildren in the
developing world, where diarrhea linked to enterotoxigenic E. coli
most common causes of travelers' diarrhea -- sickens 210 million chi... evaluate the safety of
the vaccine and the incidence of enterotoxigenic E. coli
(ETEC) bacteria -
the most common cause of travelers' diarrhea. No vaccine-...
Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
.... Dr. Nash developed quick swab tests to detect Listeria in
feedlots and E. coli
in processing plants. Dr. Nash also developed tests
for strep, whooping cou.... Nash designed all-natural cattle feed additives to
inhibit a dangerous E. coli
1057:H7 strain and improve feed efficiency with
"impressive results." Dr. N...
Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
...of how to deliver the molecules triggering RNAi into the
target cells and diseased tissues. In a proprietary process, we modify
live, nonpathogenic E. coli
bacteria to produce and deposit mediators of
RNA interference (short hairpin RNA) directly into the target cells. The
nonpathogenic bacteria are subse...
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
...ety of human food and water supplies. Its most
significant initiative is a vaccine that, when administered to cattle,
reduces the level of Escherichia coli
(E. coli) O157:H7 that can be shed
into the environment, thereby seeking to reduce human illnesses from
contaminated food and water. The vaccine has b...
Increasing Dairy Milk Production with Electrolyzed Drinking Water
...mples collected from the
troughs over the course of the study showed the EAU treated water was
consistently negative for coliform organisms such as E. coli
bacteria. Blood chemistry tests conducted also showed that blood urea
nitrogen, creatinine, magnesium and chloride levels were lower in trea...
Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
...lp greatly to reduce the
spread of certain virulent, antibiotic-resistant pathogens, such as
methicillin-resistant Staphylococcus aureus (MRSA) and E. coli
O157:H7." The clinical trials follow peer-reviewed research conducted at the
University of Southampton in the U.K. proving copper, brass and bronze c...
Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
...er and Co-Founder of Paratek. In addition, Paratek announced a newly released publication showing
efficacy of the Company's MAR inhibitors against E. coli
in urinary tract
infection in another animal model of serious bacterial infection. The
article, titled, "Novel anti-infection agents: Small-molecule i...
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
S. aureus (MSSA) (91% vs. 92%, respectively); MRSA (87% vs. 86%); S.
pyogenes (90% vs. 100%); S. agalactiae (81% vs. 75%); E. coli
92%); P. aeruginosa (83% vs. 89%); and, Enterobacter spp., Klebsiella
pneumoniae, and Proteus mirabilis (86% vs. 83%) from the site of infect...
K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
...in April 2008. Nagaraja will present "Escherichia coli
0157 and Food Safety" at 9 a.m.
He will discuss how Escherichia coli
O157 has emerged as a major foodborne
pathogen. Nagaraja studies the ecology of E. coli
O157 in cattle and is
working to identify interven...
Iomai Announces Data from Phase 2 Field Study of Travelers' Diarrhea Vaccine Accepted for Presentation at ICAAC
...AAC), to be held in Chicago Sept. 17 to 20. The abstract, "Transcutaneous Immunization with the Heat Labile Toxin
(LT) of Enterotoxigenic Escherichia coli
(ETEC) Protects in a Phase 2 Field
Trial in Travelers to Guatemala and Mexico," will be presented by Gregory
Glenn, M.D., Iomai's chief scientific off...
Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
...ent pathogens which are the source of
many hospital- acquired infections, including methicillin-resistant
Staphylococcus aureus (MRSA) and Escherichia coli
O157:H7. The U.S. Centers
for Disease Control and Prevention (CDC) estimates that infections acquired
in U.S. hospitals affect some two million indivi...
Vaxiion Researchers Discover Novel Vaccine Delivery System in
Collaboration with San Diego State University
... on the study.
"Based on the success of this translational work, Vaxiion is
developing a multi-component vaccine against Salmonella, Shigella
and E. coli
for use in human clinical trials," Sabbadini said.
Other co-authors of the study include Yen-Lin Chu of SDSU; Neil
L. Berkley, co-founder of Vaxiion...
Adnexus Therapeutics Announces Presentation at the American
Association for Cancer Research (AACR) on Clinical Product
...align with properties of successful drugs, including high potency,
specificity, stability, favorable half life, favorable IP profile
and high yield E. coli
Adnectins are designed using the PROfusion System, Adnexus'
patented protein design engine, to achieve high potency and
specificity for ...
Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for
Travelers' Diarrhea Stimulates Immune Response Even at Low Doses
...avelers' diarrhea. The trial was conducted to assess
the ability of a range of vaccine doses to generate an immune
response against enterotoxigenic E. coli
(ETEC) bacteria -- the
most common cause of travelers' diarrhea. Researchers found that
even at the lowest dose tested, an Iomai patch applied to the ...
Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical
regarding market growth; (4) the cost, timing, scope and results of
ongoing safety and efficacy trials of CholeraGarde(R) (Peru-15),
Ty800, ETEC E. coli
vaccine and other preclinical and clinical
testing; (5) the ability to negotiate strategic partnerships or
other disposition transactions for AVANT's ...
Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical
...rch and further development, including animal,
pre-clinical and clinical studies, and commercialization of
CholeraGarde® (Peru-15), Ty800, ETEC E. coli
vaccine, VLPs and
other products and AVANT’s expectations regarding market
growth; (4) the cost, timing, scope and results of ongoing safety
Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data
oncology. Thallion’s clinical-stage programs include:
Shigamabs®, a dual antibody product for the treatment of
Shigatoxin-producing E. coli
bacterial infections; ECO-4601, a
novel anticancer therapy derived from a nonpathogenic
microorganism; and CAP-232, a targeted therapy with potential
NIEHS Researchers Identify Enzyme Critical in DNA Replication
...ading strand polymerase, followed slightly
thereafter by replication of the lagging strand by a different
In lower organisms like the E. coli
bacteria that Kornberg
studied, one DNA polymerase can accomplish both tasks. However,
humans and related higher organisms, such as bakers yeast, are ...